Loading…
for educational and safety purposes
3-MeO-PCP and 3-HO-PCP both come up in the same conversations; they overlap on Glutamate. 3-MeO-PCP: 3-MeO-PCP (3-methoxyphencyclidine) is a dissociative new psychoactive substance of the arylcyclohexylamine (phencyclidine) class. 3-HO-PCP: 3-HO-PCP (3-hydroxyphencyclidine) is a hydroxylated analog of phencyclidine that acts as an NMDA receptor antagonist and, unusually for a dissociative, also displays notable mu-opioid receptor activity arising from its 3-hydroxy group; it is reported to be more potent than PCP itself.
3-MeO-PCP (3-methoxyphencyclidine) is a dissociative new psychoactive substance of the arylcyclohexylamine (phencyclidine) class. It acts principally as an antagonist at the N-methyl-D-aspartate (NMDA) glutamate receptor and is additionally reported to inhibit monoamine reuptake, giving it a more stimulating and dopaminergic character than ketamine; the closely related analogs 4-MeO-PCP and 3-MeO-PCMo have been shown to engage the mesolimbic dopamine pathway to produce rewarding and reinforcing effects. It is considerably more potent and longer-acting than ketamine, which contributes to a narrow margin between recreational and toxic exposure. The compound has been implicated in numerous non-fatal intoxications and deaths, and its metabolism and analytical detection have been characterized in forensic casework and in silico ADME studies. Because standard phencyclidine immunoassays detect it inconsistently, laboratory confirmation generally relies on chromatographic and mass-spectrometric methods.
3-HO-PCP (3-hydroxyphencyclidine) is a hydroxylated analog of phencyclidine that acts as an NMDA receptor antagonist and, unusually for a dissociative, also displays notable mu-opioid receptor activity arising from its 3-hydroxy group; it is reported to be more potent than PCP itself. This dual mechanism can add opioid-like sedation and respiratory risk to the expected dissociative effects. Analytically confirmed case reports document severe toxicity, including hyperthermia, tachycardia, rhabdomyolysis, and serotonergic features, and forensic studies have quantified the drug and mapped its hepatic metabolism, noting brain concentrations exceeding those in blood. In silico work flags moderate acute toxicity and potential cardiotoxicity, while controlled human data remain absent.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
antagonist
Antagonist
reuptake inhibitor
agonist
Agonist
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.